<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7536932\results\search\disease\results.xml">
  <result pre="Inc.Hoboken pmcid: 7536932 doi: 10.1002/rmv.2163RMV2163 : Review: Reviews Azithromycin in" exact="viral" post="infections Oliver and Hinks OliverMadeleine E.1HinksTimothy S. C.https://orcid.org/0000-0003-0699-23732timothy.hinks@ndm.ox.ac.uk[1], New"/>
  <result pre="pmcid: 7536932 doi: 10.1002/rmv.2163RMV2163 : Review: Reviews Azithromycin in viral" exact="infections" post="Oliver and Hinks OliverMadeleine E.1HinksTimothy S. C.https://orcid.org/0000-0003-0699-23732timothy.hinks@ndm.ox.ac.uk[1], New College,"/>
  <result pre="College, University of OxfordOxfordUK[2], Nuffield Department of Medicine Experimental Medicine," exact="Respiratory" post="Medicine Unit and National Institute for Health Research (NIHR),"/>
  <result pre="Timothy S. C. Hinks, Nuffield Department of Medicine Experimental Medicine," exact="Respiratory" post="Medicine Unit and National Institute for Health Research (NIHR),"/>
  <result pre="a synthetic macrolide antibiotic effective against a broad range of" exact="bacterial" post="and mycobacterial infections. Due to an additional range of"/>
  <result pre="expression of antiâ€�viral pattern recognition receptors and induction of antiâ€�viral" exact="type I" post="and III interferon responses. Of relevance to severe coronavirusâ€�19"/>
  <result pre="I and III interferon responses. Of relevance to severe coronavirusâ€�19" exact="disease" post="(COVIDâ€�19), which is characterised by an overâ€�exuberant innate inflammatory"/>
  <result pre="Centre (BRC) fig-count: table-count: page-count: word-count: OliverME, HinksTSC. Azithromycin in" exact="viral" post="infections. Rev Med Virol. 2020;e216310.1002/rmv.216332969125 Funding information University of"/>
  <result pre="Oxford Biomedical Research Centre (BRC) Abbreviations AZM azithromycin CAP community" exact="acquired" post="pneumonia CCL Câ€�C motif ligand CD cluster of differentiation"/>
  <result pre="Biomedical Research Centre (BRC) Abbreviations AZM azithromycin CAP community acquired" exact="pneumonia" post="CCL Câ€�C motif ligand CD cluster of differentiation CF"/>
  <result pre="pneumonia CCL Câ€�C motif ligand CD cluster of differentiation CF" exact="cystic fibrosis" post="COVIDâ€�19 coronavirusâ€�19 disease COX cyclooxygenase cPLA2 cytosolic phospholipase A2"/>
  <result pre="ligand CD cluster of differentiation CF cystic fibrosis COVIDâ€�19 coronavirusâ€�19" exact="disease" post="COX cyclooxygenase cPLA2 cytosolic phospholipase A2 CRP Câ€�reactive protein"/>
  <result pre="differentiation CF cystic fibrosis COVIDâ€�19 coronavirusâ€�19 disease COX cyclooxygenase cPLA2" exact="cytosolic" post="phospholipase A2 CRP Câ€�reactive protein CXCL Câ€�Xâ€�C motif ligand"/>
  <result pre="phospholipase A2 CRP Câ€�reactive protein CXCL Câ€�Xâ€�C motif ligand DPB" exact="diffuse" post="panbronchiolitis ERK extracellular signalâ€�regulated kinase GMâ€�CSF granulocyteâ€�macrophage colonyâ€�stimulating factor"/>
  <result pre="molecular weight heparin MAPK mitogenâ€�activated protein kinase MCL1 myeloid cell" exact="leukaemia" post="sequence 1 MDA5 melanoma differentiationâ€�associated protein 5 MxA myxoma"/>
  <result pre="mitogenâ€�activated protein kinase MCL1 myeloid cell leukaemia sequence 1 MDA5" exact="melanoma" post="differentiationâ€�associated protein 5 MxA myxoma virus resistance A NALP3"/>
  <result pre="cell leukaemia sequence 1 MDA5 melanoma differentiationâ€�associated protein 5 MxA" exact="myxoma" post="virus resistance A NALP3 NACHT, LRR, and PYD domainsâ€�containing"/>
  <result pre="and PYD domainsâ€�containing protein 3 NCT National Clinical Trial PBEC" exact="primary" post="bronchial epithelial cell PGE2 prostaglandin E2 PRR pattern recognition"/>
  <result pre="domainsâ€�containing protein 3 NCT National Clinical Trial PBEC primary bronchial" exact="epithelial" post="cell PGE2 prostaglandin E2 PRR pattern recognition receptor RIGâ€�1"/>
  <result pre="receptor RIGâ€�1 retinoic acidâ€�inducible gene 1 RV rhinovirus SARS severe" exact="acute" post="respiratory syndrome TBK1 TANKâ€�binding kinase 1 TGFâ€�beta transforming growth"/>
  <result pre="RIGâ€�1 retinoic acidâ€�inducible gene 1 RV rhinovirus SARS severe acute" exact="respiratory" post="syndrome TBK1 TANKâ€�binding kinase 1 TGFâ€�beta transforming growth factor"/>
  <result pre="retinoic acidâ€�inducible gene 1 RV rhinovirus SARS severe acute respiratory" exact="syndrome" post="TBK1 TANKâ€�binding kinase 1 TGFâ€�beta transforming growth factor beta"/>
  <result pre="the early 1980s1, 2 to treat a wide range of" exact="bacterial" post="and mycobacterial infections of respiratory and skin infections. It"/>
  <result pre="2 to treat a wide range of bacterial and mycobacterial" exact="infections" post="of respiratory and skin infections. It is therefore on"/>
  <result pre="treat a wide range of bacterial and mycobacterial infections of" exact="respiratory" post="and skin infections. It is therefore on the WHO"/>
  <result pre="potential candidate treatment for viruses including SARSâ€�CoVâ€�2, which causes coronavirusâ€�19" exact="disease" post="(COVIDâ€�19). It has been used as a treatment in"/>
  <result pre="treatment in previous coronavirus diseases during the epidemics of severe" exact="acute" post="respiratory syndrome (SARS) in 2003 and Middle East respiratory"/>
  <result pre="in previous coronavirus diseases during the epidemics of severe acute" exact="respiratory" post="syndrome (SARS) in 2003 and Middle East respiratory syndrome"/>
  <result pre="previous coronavirus diseases during the epidemics of severe acute respiratory" exact="syndrome" post="(SARS) in 2003 and Middle East respiratory syndrome (MERS)5"/>
  <result pre="severe acute respiratory syndrome (SARS) in 2003 and Middle East" exact="respiratory" post="syndrome (MERS)5 in 2012, but to date there are"/>
  <result pre="acute respiratory syndrome (SARS) in 2003 and Middle East respiratory" exact="syndrome" post="(MERS)5 in 2012, but to date there are no"/>
  <result pre="of antiâ€�viral activity of macrolides across a broad range of" exact="viral" post="species and families (Table 1). Some studies suggest improved"/>
  <result pre="studies have observed these effects.23, 24, 25, 26 TABLE 1" exact="Viral" post="infections in which azithromycin has demonstrated antiâ€�viral effects Pathogen"/>
  <result pre="have observed these effects.23, 24, 25, 26 TABLE 1 Viral" exact="infections" post="in which azithromycin has demonstrated antiâ€�viral effects Pathogen Findings"/>
  <result pre="effects Pathogen Findings Method Study Human rhinovirus (Picornavirus) Enhanced viralâ€�induced" exact="type I" post="and III IFN leading to reduced RV replication and"/>
  <result pre="vitro study. PBEC. 10 Î¼M, 50 Î¼M Gielen et al7" exact="Reduced" post="RV replication In vitro study. PBEC from cystic fibrosis"/>
  <result pre="et al7 Reduced RV replication In vitro study. PBEC from" exact="cystic fibrosis" post="patients. 50 Î¼M Schogler et al8 In vitro study."/>
  <result pre="et al9 Coronaviruses (alpha and beta) AZM associated with reduced" exact="viral" post="load in children with coronaviruses Clinical trial. Dose â‰¥20"/>
  <result pre="â‰¥20 mg/kg Doan et al10 Zika (Flavivirus) AZM markedly reduces" exact="viral" post="proliferation and virusâ€�induced cytopathic effects In vitro study. U87"/>
  <result pre="0 Î¼M to &amp;gt;100 Î¼M Retallack et al11 AZM upregulates" exact="type I" post="and III interferon responses In vitro study. HTâ€�29 human"/>
  <result pre="and III interferon responses In vitro study. HTâ€�29 human colon" exact="epithelial" post="cell line and A549 lung epithelial cell line. 10"/>
  <result pre="study. HTâ€�29 human colon epithelial cell line and A549 lung" exact="epithelial" post="cell line. 10 Î¼M, 50 Î¼M Li et al12"/>
  <result pre="line. 10 Î¼M, 50 Î¼M Li et al12 AZM upregulates" exact="viral" post="pathogen recognition receptors MDA5 and RIGâ€�1 In vitro study."/>
  <result pre="recognition receptors MDA5 and RIGâ€�1 In vitro study. A549 lung" exact="epithelial" post="cell line. 10 Î¼M, 50 Î¼M AZM increases levels"/>
  <result pre="phosphorylated TBK1 and IRF3 In vitro study. HTâ€�29 human colon" exact="epithelial" post="cell line, 10 Î¼M, 50 Î¼M Human primary fibroblasts,"/>
  <result pre="human colon epithelial cell line, 10 Î¼M, 50 Î¼M Human" exact="primary" post="fibroblasts, 5 Î¼M, 20 Î¼M. RAW264.7 macrophage cells 1.5"/>
  <result pre="interferon; IRF3, Interferon Regulatory Factor 3; ISG, interferonâ€�stimulated gene; MDA5," exact="melanoma" post="differentiationâ€�associated protein 5; MxA, myxoma virus resistance A; PBEC,"/>
  <result pre="3; ISG, interferonâ€�stimulated gene; MDA5, melanoma differentiationâ€�associated protein 5; MxA," exact="myxoma" post="virus resistance A; PBEC, primary bronchial epithelial cell; PRR,"/>
  <result pre="melanoma differentiationâ€�associated protein 5; MxA, myxoma virus resistance A; PBEC," exact="primary" post="bronchial epithelial cell; PRR, pattern recognition receptor; RIGâ€�1, retinoic"/>
  <result pre="protein 5; MxA, myxoma virus resistance A; PBEC, primary bronchial" exact="epithelial" post="cell; PRR, pattern recognition receptor; RIGâ€�1, retinoic acidâ€�inducible gene"/>
  <result pre="receptor; RIGâ€�1, retinoic acidâ€�inducible gene 1, RV, rhinovirus; SARS, severe" exact="acute" post="respiratory syndrome; TBK1, TANKâ€�binding kinase 1. 2.1 Mechanisms of"/>
  <result pre="RIGâ€�1, retinoic acidâ€�inducible gene 1, RV, rhinovirus; SARS, severe acute" exact="respiratory" post="syndrome; TBK1, TANKâ€�binding kinase 1. 2.1 Mechanisms of antiâ€�viral"/>
  <result pre="30 As the majority of such exacerbations are triggered by" exact="viral" post="infections,31 most commonly rhinoviruses (RV),32 the effects of macrolides"/>
  <result pre="RV. AZM reduces RV replication and release during in vitro" exact="infection" post="of primary human bronchial epithelial cells (PBEC).7 This finding"/>
  <result pre="reduces RV replication and release during in vitro infection of" exact="primary" post="human bronchial epithelial cells (PBEC).7 This finding was replicated"/>
  <result pre="and release during in vitro infection of primary human bronchial" exact="epithelial" post="cells (PBEC).7 This finding was replicated in PBEC from"/>
  <result pre="(PBEC).7 This finding was replicated in PBEC from patients with" exact="cystic fibrosis" post="or healthy controls, where AZM treatment again led to"/>
  <result pre="treatment again led to a sevenfold to ninefold reduction in" exact="viral" post="shedding, respectively.8 The use of AZM alone increased viralâ€�induced"/>
  <result pre="of these gene products.7, 8 In the latter study, while" exact="viral" post="replication was suppressed, AZM did not suppress proâ€�inflammatory responses."/>
  <result pre="macrolide in airways disease, showed a striking 40% reduction in" exact="asthma" post="exacerbations with AZM.29 The mechanism is unknown, and would"/>
  <result pre="rhinovirus (RV).35 Other macrolides also have antiâ€�viral effects in RV" exact="infection" post="including Mac5, an oleandomycin macrolide. Both AZM and Mac5"/>
  <result pre="Both AZM and Mac5 suppressed RV replication and enhanced RVâ€�induced" exact="type I" post="and type III IFNs, as well as the ISGs"/>
  <result pre="Mac5 suppressed RV replication and enhanced RVâ€�induced type I and" exact="type III" post="IFNs, as well as the ISGs viperin/MxA.9 In this"/>
  <result pre="macrolide) in a separate study of RV,36 alongside inhibition of" exact="viral" post="replication and ICAMâ€�1. Macrolides such as AZM augment infectionâ€�induced"/>
  <result pre="infectionâ€�induced IFN responses.9 This is of relevance to coronaviruses as" exact="type I" post="IFN inhibit replication of both SARSâ€�CoV37 and SARSâ€�CoVâ€�238 in"/>
  <result pre="reduced RVâ€�induced NFÎºB activation and decreased acidity of endosomes in" exact="epithelial" post="cells. Bafilomycin inhibited cytokine production and ICAMâ€�1 expression. 2.2"/>
  <result pre="and the effect was small, with no significant changes in" exact="viral" post="clearance or time to symptom resolution. In a second,"/>
  <result pre="influenza.18 The effect size was marked, although the study is" exact="limited" post="by lack of blinding and by the likelihood that"/>
  <result pre="might be attributable to the antibacterial properties of clarithromycin, as" exact="bacterial" post="pneumonias are responsible for a high proportion of influenza"/>
  <result pre="deaths, particularly in the elderly. Nonetheless in vitro clarithromycin reduced" exact="viral" post="replication in the A549 human lung cell line.41 Likewise"/>
  <result pre="in the A549 human lung cell line.41 Likewise clarithromycin reduced" exact="viral" post="titres and supernatant cytokines on cultured human tracheal epithelial"/>
  <result pre="reduced viral titres and supernatant cytokines on cultured human tracheal" exact="epithelial" post="cells, associated with reduction in surface expression of the"/>
  <result pre="reduced acidification of the endosome required for intracellular release of" exact="viral" post="RNA.42 More recent data also showed a reduction in"/>
  <result pre="RNA.42 More recent data also showed a reduction in H1N1" exact="viral" post="replication in A549 cells with AZM with an IC50"/>
  <result pre="IC50 of 68 Î¼M, with an effect most apparent during" exact="viral" post="particle internalisation.43 Some murine studies have investigated macrolides in"/>
  <result pre="derivative (EM900) each reduced weight loss, improved survival and reduced" exact="viral" post="protein expression in H1N1 influenza.45 In a shortâ€�term H1N1"/>
  <result pre="viral protein expression in H1N1 influenza.45 In a shortâ€�term H1N1" exact="infection" post="model, AZM reduced expression of viral proteins 2â€‰days post"/>
  <result pre="In a shortâ€�term H1N1 infection model, AZM reduced expression of" exact="viral" post="proteins 2â€‰days post infection.43 However, the effect was not"/>
  <result pre="measurement of influenza pathology. Another study found AZM reduced lung" exact="viral" post="titres at day 6 post infection, though the effects"/>
  <result pre="additive to that achieved with oseltamivir in terms of survival," exact="viral" post="titres or cytokine levels,46 and so these data remain"/>
  <result pre="data remain conflicting.47 In a separate influenza study, AZM decreased" exact="total" post="leukocyte accumulation in lung tissue and BAL, with the"/>
  <result pre="screen of 2177 compounds against the flavivirus Zika, AZM reduced" exact="viral" post="proliferation and virusâ€�induced cytopathic effects in glial cell lines"/>
  <result pre="further in vitro study found AZM to effectively suppress Zika" exact="infection" post="by targeting a late stage in the viral life"/>
  <result pre="suppress Zika infection by targeting a late stage in the" exact="viral" post="life cycle.12 AZM also upregulated expression of type I"/>
  <result pre="in the viral life cycle.12 AZM also upregulated expression of" exact="type I" post="and III IFNs and several of their downstream ISGs,"/>
  <result pre="pigs. 2.5 Antiâ€�viral effects in enteroviruses Enterovirus A71 (EVâ€�A71) causes" exact="hand, foot and mouth disease" post="in young children. AZM and spiramycin (another macrolide) provided"/>
  <result pre="in enteroviruses Enterovirus A71 (EVâ€�A71) causes hand, foot and mouth" exact="disease" post="in young children. AZM and spiramycin (another macrolide) provided"/>
  <result pre="spiramycin (another macrolide) provided significant in vivo protection against EVâ€�A71" exact="infection" post="in mice.13 Spiramycin impaired EVâ€�A71 viral RNA synthesis, and"/>
  <result pre="vivo protection against EVâ€�A71 infection in mice.13 Spiramycin impaired EVâ€�A71" exact="viral" post="RNA synthesis, and it is likely spiramycin and AZM"/>
  <result pre="likely spiramycin and AZM work through a common mechanism, after" exact="viral" post="entry, impairing viral RNA synthesis either directly or indirectly."/>
  <result pre="AZM work through a common mechanism, after viral entry, impairing" exact="viral" post="RNA synthesis either directly or indirectly. 2.6 Antiâ€�viral effects"/>
  <result pre="four genera (Alphaâ€�, Betaâ€�, Gammaâ€�, Deltaâ€�coronaviruses).48 These viruses are endemic" exact="respiratory" post="and gastrointestinal viruses and the Betacoronavirus genus includes the"/>
  <result pre="placebo every 6 months and nasopharyngeal swabs were taken for" exact="viral" post="RNA sequencing. After 24â€‰months, AZM use was associated with"/>
  <result pre="24â€‰months, AZM use was associated with an eightfold reduction in" exact="viral" post="load of Alphacoronavirus and a 14â€�fold reduction in Betacoronavirus"/>
  <result pre="viral load of Alphacoronavirus and a 14â€�fold reduction in Betacoronavirus" exact="viral" post="load, though there was no difference in the prevalence"/>
  <result pre="approved and offâ€�patent drugs identified 90 drugs which inhibited SARSâ€�CoVâ€�2" exact="viral" post="replication at 10 Î¼M.48 These included ATPase proton pump"/>
  <result pre="10 Î¼M.48 These included ATPase proton pump inhibitors, protease inhibitors," exact="viral" post="protease inhibitors, drugs targeting the angiotensin pathway and AZM."/>
  <result pre="drawn. Moreover, there are concerns that combination therapy may enhance" exact="cardiovascular" post="side effects as both molecules individually can cause prolongation"/>
  <result pre="effects on the infected cells, morbidity and mortality in severe" exact="disease" post="are typically attributable to the host inflammatory response, including"/>
  <result pre="which have proven clinical efficacy in a broad range of" exact="respiratory" post="diseases including asthma,29 COPD,58 post lung transplant obliterative bronchiolitis59"/>
  <result pre="diseases including asthma,29 COPD,58 post lung transplant obliterative bronchiolitis59 and" exact="diffuse" post="pan bronchiolitis (DPB).60, 61, 62, 63 In DPB, a"/>
  <result pre="asthma,29 COPD,58 post lung transplant obliterative bronchiolitis59 and diffuse pan" exact="bronchiolitis" post="(DPB).60, 61, 62, 63 In DPB, a dramatic increase"/>
  <result pre="Figure 1) may be clinically important in the management of" exact="viral" post="diseases. TABLE 2 Immunomodulatory and antiâ€�inflammatory properties of azithromycin"/>
  <result pre="and antiâ€�inflammatory properties of azithromycin Property Effect Specific Findings Study" exact="General" post="antiâ€�inflammatory properties Destabilisation of NALP3 mRNA levels Decreased ILâ€�beta"/>
  <result pre="inflammatory cytokine release Decreased CXCL8 (ILâ€�8), NFÎºB and APâ€�1 from" exact="epithelial" post="cells Clinical trial in recurrent genital C. trachomatis infection."/>
  <result pre="(ILâ€�8), NFÎºB and APâ€�1 from epithelial cells Clinical trial in" exact="recurrent" post="genital C. trachomatis infection. Decreased ILâ€�1beta, CXCLâ€�1, â€�5, â€�8,"/>
  <result pre="â€�8, â€�9, CCL2, â€�5, MCL1, MAPK1 Srivastava et al66 Airway" exact="epithelial" post="cell lines. Decrease in CXCL8 mRNA, and NFÎºB and"/>
  <result pre="al67 Decreased CXCL8 (ILâ€�8), MAPK and 8â€�isoprostane in airway smooth" exact="muscle" post="cells ILâ€�17â€�stimulated primary human airway smooth muscle cells Vanaudenaerde"/>
  <result pre="(ILâ€�8), MAPK and 8â€�isoprostane in airway smooth muscle cells ILâ€�17â€�stimulated" exact="primary" post="human airway smooth muscle cells Vanaudenaerde et al68 Decreased"/>
  <result pre="in airway smooth muscle cells ILâ€�17â€�stimulated primary human airway smooth" exact="muscle" post="cells Vanaudenaerde et al68 Decreased PGE2 synthesis Human polymorphonuclear"/>
  <result pre="of cPLA2, COXâ€�1, COXâ€�2 Miyazaki et al69 Decreased TNF from" exact="cystic fibrosis" post="airway epithelial cells Human CF and nonâ€�CF cell lines."/>
  <result pre="COXâ€�2 Miyazaki et al69 Decreased TNF from cystic fibrosis airway" exact="epithelial" post="cells Human CF and nonâ€�CF cell lines. Decreased TNF"/>
  <result pre="NFÎºB and Sp1 binding Cigana et al70 Decreased GMâ€�CSF Airway" exact="epithelial" post="(A549) cell lines. Reduced TNFâ€�induced GMâ€�CSF mRNA and protein"/>
  <result pre="Cigana et al70 Decreased GMâ€�CSF Airway epithelial (A549) cell lines." exact="Reduced" post="TNFâ€�induced GMâ€�CSF mRNA and protein expression Yamasawa et al71"/>
  <result pre="Yamasawa et al71 Reduction of cytokineâ€�induced endothelin 1 expression in" exact="epithelial" post="cells Human bronchial epithelial cells. Erythromycin and clarithromycin reduced"/>
  <result pre="of cytokineâ€�induced endothelin 1 expression in epithelial cells Human bronchial" exact="epithelial" post="cells. Erythromycin and clarithromycin reduced enfothelinâ€�1 expression Takizawa et"/>
  <result pre="al74 Increase of lysosomal hydrolase activity in fibroblasts Fibroblast homogenates." exact="Increased" post="activity of sulfatase A, phospholipase A1, cathepsin B Gerbaux"/>
  <result pre="neutrophils. Concentration in alveolar macrophages, in neutrophils, in phagocytic and" exact="epithelial" post="cell lines Wildfeuer et al, Capitano et al, Bosnar"/>
  <result pre="Inhibition of neutrophil chemotaxis Murine pseudomonas model and human neutrophils." exact="Reduced" post="neutrophil chemotaxis via ERKâ€�1 and ERKâ€�2 Tsai et al82"/>
  <result pre="in vivo blood neutrophils. Decreased MPO concentration CuliÄ‡ et al84" exact="Increased" post="neutrophil apoptosis Human in vivo blood neutrophils. Increased neutrophil"/>
  <result pre="et al84 Increased neutrophil apoptosis Human in vivo blood neutrophils." exact="Increased" post="neutrophil apoptosis 28â€‰days post dose CuliÄ‡ et al84 Inhibition"/>
  <result pre="reduced airway neutrophil elastase and MMP9 Simpson et al86 Macrophages" exact="Increased" post="phagocytosis Human alveolar macrophages. Increased phagocytosis of apoptotic bronchial"/>
  <result pre="MMP9 Simpson et al86 Macrophages Increased phagocytosis Human alveolar macrophages." exact="Increased" post="phagocytosis of apoptotic bronchial epithelial cells and neutrophils Hodge"/>
  <result pre="Increased phagocytosis Human alveolar macrophages. Increased phagocytosis of apoptotic bronchial" exact="epithelial" post="cells and neutrophils Hodge et al, Yamaryo et al87,"/>
  <result pre="more resistant to oxidant challenge Human alveolar macrophages ex vivo." exact="Reduced" post="oxidative lysosomal membrane permeabilisation Persson et al89 Polarization towards"/>
  <result pre="towards M2 phenotype In vitro polarised J774 macrophage cell line." exact="Increased" post="M2 markers mannose receptor, CD23, arginase, decreased CCR7 Murphy"/>
  <result pre="induction by inhibited APâ€�1, NFAT, ICSBP binding Yamauchi et al92" exact="Increased" post="mannose receptor expression Human in vivo trial. Increased mannose"/>
  <result pre="et al92 Increased mannose receptor expression Human in vivo trial." exact="Increased" post="mannose receptor expression and phagocytosis Hodge et al93 Decreased"/>
  <result pre="Lin et al99 Effects on airway mucosal stromal cells Smooth" exact="muscle" post="cells Antiproliferative effect Rabbit tracheal smooth muscle cells. Reduced"/>
  <result pre="stromal cells Smooth muscle cells Antiproliferative effect Rabbit tracheal smooth" exact="muscle" post="cells. Reduced proliferation, increased autophagy Stamatiou et al100 Relaxant"/>
  <result pre="Smooth muscle cells Antiproliferative effect Rabbit tracheal smooth muscle cells." exact="Reduced" post="proliferation, increased autophagy Stamatiou et al100 Relaxant effect Rabbit"/>
  <result pre="increased autophagy Stamatiou et al100 Relaxant effect Rabbit tracheal smooth" exact="muscle" post="cells. Smooth muscle relaxation Daenas et al101 Airway epithelium"/>
  <result pre="et al100 Relaxant effect Rabbit tracheal smooth muscle cells. Smooth" exact="muscle" post="relaxation Daenas et al101 Airway epithelium Enhanced airway epithelial"/>
  <result pre="Smooth muscle relaxation Daenas et al101 Airway epithelium Enhanced airway" exact="epithelial" post="integrity Increased transepithelial electrical resistance by altered processing of"/>
  <result pre="relaxation Daenas et al101 Airway epithelium Enhanced airway epithelial integrity" exact="Increased" post="transepithelial electrical resistance by altered processing of tight junction"/>
  <result pre="103 Inhibition of inflammatory mucin release Human cell lines and" exact="primary" post="cells. Inhibition of MUC5AC production Imamura et al, Ribeiro"/>
  <result pre="Ribeiro et al104, 105 Modulated CXCL8 (ILâ€�8) production Human bronchial" exact="epithelial" post="cells. Increased CXCL8 release Shinkai et al106 Reduced CXCL8"/>
  <result pre="al104, 105 Modulated CXCL8 (ILâ€�8) production Human bronchial epithelial cells." exact="Increased" post="CXCL8 release Shinkai et al106 Reduced CXCL8 (ILâ€�8) Human"/>
  <result pre="Human bronchial epithelial cells. Increased CXCL8 release Shinkai et al106" exact="Reduced" post="CXCL8 (ILâ€�8) Human trial. Roxithromycin reduced CXCL8 in nasal"/>
  <result pre="(ILâ€�8) Human trial. Roxithromycin reduced CXCL8 in nasal lavage in" exact="chronic" post="rhinosinusitis, with clinical improvement Wallwork et al, Yamada et"/>
  <result pre="Abbreviations: CCL, Câ€�C motif ligand; CD, cluster of differentiation; CF," exact="cystic fibrosis;" post="CXCL, Câ€�Xâ€�C motif ligand; DPB, diffuse panbronchiolitis; COX, cyclooxygenase;"/>
  <result pre="of differentiation; CF, cystic fibrosis; CXCL, Câ€�Xâ€�C motif ligand; DPB," exact="diffuse" post="panbronchiolitis; COX, cyclooxygenase; cPLA2, cytosolic phospholipase A2; ERK, extracellular"/>
  <result pre="CXCL, Câ€�Xâ€�C motif ligand; DPB, diffuse panbronchiolitis; COX, cyclooxygenase; cPLA2," exact="cytosolic" post="phospholipase A2; ERK, extracellular signalâ€�regulated kinase; GMâ€�CSF, granulocyteâ€�macrophage colonyâ€�stimulating"/>
  <result pre="(CSF2); IL, interleukin; MAPK, mitogenâ€�activated protein kinase; MCL1, myeloid cell" exact="leukaemia" post="sequence 1; NALP3, NACHT, LRR, and PYD domainsâ€�containing protein"/>
  <result pre="interleukin; IRF3, Interferon Regulatory Factor 3; ISG, interferonâ€�stimulated gene; MDA5," exact="melanoma" post="differentiationâ€�associated protein 5; MPO, myeloperoxidase; MxA, myxoma resistance protein"/>
  <result pre="interferonâ€�stimulated gene; MDA5, melanoma differentiationâ€�associated protein 5; MPO, myeloperoxidase; MxA," exact="myxoma" post="resistance protein 1; NFÎºB, nuclear factor kappa B; NLRP3,"/>
  <result pre="macrolides is that they can accumulate in host cells including" exact="epithelial" post="cells and most particularly in phagocytes where they may"/>
  <result pre="have observed initial stimulatory effects of AZM on immune and" exact="epithelial" post="cells. Acutely, AZM stimulates neutrophil degranulation and phagocytosisâ€�associated oxidative"/>
  <result pre="a component of NFÎºB117 and attenuates NFÎºB activation in lung" exact="epithelial" post="cells.118 This inhibition reduces epithelial cell ILâ€�8 production,67, 118"/>
  <result pre="attenuates NFÎºB activation in lung epithelial cells.118 This inhibition reduces" exact="epithelial" post="cell ILâ€�8 production,67, 118 stromal cell proliferation66 and macrophage"/>
  <result pre="Macrolides including AZM can also increase the phagocytosis of apoptotic" exact="epithelial" post="cells121 and neutrophils by macrophages,87 which can ameliorate inflammation."/>
  <result pre="regulation of perforin.98 AZM may have antiâ€�inflammatory effects directly on" exact="epithelial" post="cells, such as suppression of GMâ€�CSF release,99 TNF,114 inhibition"/>
  <result pre="for inflammationâ€�induced changes in airway mucus.71, 122 Macrolides inhibit airway" exact="epithelial" post="cell mucus secretion123 and directly inhibit neutrophil elastase.124, 125"/>
  <result pre="inhibit neutrophil elastase.124, 125 Another effect of macrolides on airway" exact="epithelial" post="cells observed in vitro is increased epithelial barrier integrity"/>
  <result pre="macrolides on airway epithelial cells observed in vitro is increased" exact="epithelial" post="barrier integrity by alterations in tight junction proteins, including"/>
  <result pre="and most markedly on the accumulation, adhesion and apoptosis of" exact="pulmonary" post="neutrophils. 4 POTENTIAL CLINICAL UTILITY IN COVIDâ€�19 Beyond its"/>
  <result pre="disease, most COVIDâ€�19 related deaths occur due to sudden, late" exact="respiratory" post="failure, on average at day 14 after symptom onset,129"/>
  <result pre="average at day 14 after symptom onset,129 by which point" exact="viral" post="loads have markedly decreased. Severe COVIDâ€�19 disease is associated"/>
  <result pre="symptom onset,129 by which point viral loads have markedly decreased." exact="Severe" post="COVIDâ€�19 disease is associated with loss of alveolar macrophages130"/>
  <result pre="by which point viral loads have markedly decreased. Severe COVIDâ€�19" exact="disease" post="is associated with loss of alveolar macrophages130 and an"/>
  <result pre="significant mortality benefit with dexamethasone in patients with severe COVIDâ€�19" exact="disease" post="and respiratory failure.132 Interestingly, there was no benefit in"/>
  <result pre="benefit with dexamethasone in patients with severe COVIDâ€�19 disease and" exact="respiratory" post="failure.132 Interestingly, there was no benefit in those randomised"/>
  <result pre="Interestingly, there was no benefit in those randomised at earlier" exact="disease" post="stages, consistent with a lower degree of inflammation in"/>
  <result pre="in those randomised at earlier disease stages, consistent with a" exact="lower" post="degree of inflammation in these individuals, and suggesting other"/>
  <result pre="might be valuable. The lag between symptom onset and severe" exact="disease" post="provides a therapeutic window in which AZM antiâ€�inflammatory properties"/>
  <result pre="therapeutic window in which AZM antiâ€�inflammatory properties may reduce severe" exact="pulmonary" post="inflammation, benefiting from the propensity of macrolides to accumulate"/>
  <result pre="critically, according to the population being studied. Those recruiting in" exact="primary" post="care will tend to study the antiâ€�viral effects in"/>
  <result pre="the antiâ€�viral effects in early disease, whilst those recruiting in" exact="secondary" post="care will be studying more the antiâ€�inflammatory effects important"/>
  <result pre="0.82; 95% confidence interval 0.47â€�1.43), but data from other populations," exact="disease" post="stages and without HCQ are urgently needed. If studies"/>
  <result pre="pregnancy and known hypersensitivity. Whilst there have been concerns about" exact="cardiovascular" post="risk, huge epidemiological studies suggest these are very small"/>
  <result pre="is of particular concern. Widespread use of AZM to treat" exact="viral" post="infections runs an inevitable risk of increasing the development"/>
  <result pre="of particular concern. Widespread use of AZM to treat viral" exact="infections" post="runs an inevitable risk of increasing the development of"/>
  <result pre="90% for Mycoplasma pneumoniae and nearly 100% for S. pneumoniae.110" exact="Resistance" post="is a particularly high risk with macrolides due to"/>
  <result pre="halfâ€�life, good safety profile and very strong evidence base in" exact="bacterial diseases" post="are fascinating molecules. Macrolides undoubtedly have broadâ€�spectrum antiâ€�viral properties"/>
  <result pre="emerges as a candidate molecule in antiâ€�viral drug screens against" exact="respiratory" post="viruses, and there are tantalising hints of clinical efficacy"/>
  <result pre="prove to be clinically important in reducing immunopathology in some" exact="viral" post="diseases, not least against the pandemic Betacoronaviruses in which"/>
  <result pre="to perform wellâ€�designed and conducted randomised trials in patients with" exact="chronic" post="airways disorders and those with pandemic respiratory viruses including"/>
  <result pre="in patients with chronic airways disorders and those with pandemic" exact="respiratory" post="viruses including influenza A, SARSâ€�CoVâ€�2 and in future pandemics"/>
  <result pre="preparation. USA1982. 3collab: World Health Organization . Model List of" exact="Essential" post="Medicines. 21st ed.Geneva: World Health Organization; 2019. 4SchÃ¶nfeldW, KirstHA."/>
  <result pre="et al. Macrolides in critically ill patients with Middle East" exact="respiratory" post="syndrome. Int J Infect Dis. 2019;81:184â€�190.30690213 6collab: Câ€�CRCEa ."/>
  <result pre="2020;395(10233):1322â€�1325.32247324 7GielenV, JohnstonSL, EdwardsMR. Azithromycin induces antiâ€�viral responses in bronchial" exact="epithelial" post="cells. Eur Respir J. 2010;36(3):646â€�654.20150207 8SchoglerA, KopfBS, EdwardsMR, et"/>
  <result pre="KopfBS, EdwardsMR, et al. Novel antiviral properties of azithromycin in" exact="cystic fibrosis" post="airway epithelial cells. Eur Respir J. 2015;45(2):428â€�439.25359346 9PorterJD, WatsonJ,"/>
  <result pre="al. Novel antiviral properties of azithromycin in cystic fibrosis airway" exact="epithelial" post="cells. Eur Respir J. 2015;45(2):428â€�439.25359346 9PorterJD, WatsonJ, RobertsLR, et"/>
  <result pre="et al. Identification of novel macrolides with antibacterial, antiâ€�inflammatory and" exact="type I" post="and III IFNâ€�augmenting activity in airway epithelium. J Antimicrob"/>
  <result pre="et al. Zika virus cell tropism in the developing human" exact="brain" post="and inhibition by azithromycin. Proc Natl Acad Sci U"/>
  <result pre="2016;113(50):14408â€�14413.27911847 12LiC, ZuS, DengYQ, et al. Azithromycin protects against Zika" exact="virus infection" post="by upregulating virusâ€�induced type I and III interferon responses."/>
  <result pre="12LiC, ZuS, DengYQ, et al. Azithromycin protects against Zika virus" exact="infection" post="by upregulating virusâ€�induced type I and III interferon responses."/>
  <result pre="al. Azithromycin protects against Zika virus infection by upregulating virusâ€�induced" exact="type I" post="and III interferon responses. Antimicrob Agents Chemother. 2019;63(12):e00394â€&quot;19. doi:10.1128/AAC.00394-19."/>
  <result pre="AnanK, SugaM. Adjunctive therapy with azithromycin for moderate and severe" exact="acute" post="respiratory distress syndrome: a retrospective, propensity scoreâ€�matching analysis of"/>
  <result pre="SugaM. Adjunctive therapy with azithromycin for moderate and severe acute" exact="respiratory" post="distress syndrome: a retrospective, propensity scoreâ€�matching analysis of prospectively"/>
  <result pre="17ShinaharaW, TakahashiE, SawabuchiT, et al. Immunomodulator clarithromycin enhances mucosal and" exact="systemic" post="immune responses and reduces reâ€�infection rate in pediatric patients"/>
  <result pre="2014;52(5):302â€�309. 20WalkeyAJ, WienerRS. Macrolide antibiotics and survival in patients with" exact="acute" post="lung injury. Chest. 2012;141(5):1153â€�1159.22116799 21TahanF, OzcanA, KocN. Clarithromycin in"/>
  <result pre="maclorides on duration and resolution of symptoms and complication of" exact="pneumonia" post="in children with influenza. J Nippon Med Sch. 2002;69(1):53â€�57.11847511"/>
  <result pre="One. 2013;8(9):e74316.24086334 24Martinâ€�LoechesI, Bermejoâ€�MartinJF, VallesJ, et al. Macrolideâ€�based regimens in" exact="absence of" post="bacterial coâ€�infection in critically ill H1N1 patients with primary"/>
  <result pre="24Martinâ€�LoechesI, Bermejoâ€�MartinJF, VallesJ, et al. Macrolideâ€�based regimens in absence of" exact="bacterial" post="coâ€�infection in critically ill H1N1 patients with primary viral"/>
  <result pre="absence of bacterial coâ€�infection in critically ill H1N1 patients with" exact="primary" post="viral pneumonia. Intensive Care Med. 2013;39(4):693â€�702.23344833 25PintoLA, PitrezPM, LuisiF,"/>
  <result pre="of bacterial coâ€�infection in critically ill H1N1 patients with primary" exact="viral pneumonia." post="Intensive Care Med. 2013;39(4):693â€�702.23344833 25PintoLA, PitrezPM, LuisiF, et al."/>
  <result pre="PitrezPM, LuisiF, et al. Azithromycin therapy in hospitalized infants with" exact="acute" post="bronchiolitis is not associated with better clinical outcomes: a"/>
  <result pre="LuisiF, et al. Azithromycin therapy in hospitalized infants with acute" exact="bronchiolitis" post="is not associated with better clinical outcomes: a randomized,"/>
  <result pre="UiterwaalCS, KimpenJL. Dutch antibiotics in RSVTRG. Azithromycin does not improve" exact="disease" post="course in hospitalized infants with respiratory syncytial virus (RSV)"/>
  <result pre="Azithromycin does not improve disease course in hospitalized infants with" exact="respiratory" post="syncytial virus (RSV) lower respiratory tract disease: a randomized"/>
  <result pre="disease course in hospitalized infants with respiratory syncytial virus (RSV)" exact="lower" post="respiratory tract disease: a randomized equivalence trial. Pediatr Pulmonol."/>
  <result pre="course in hospitalized infants with respiratory syncytial virus (RSV) lower" exact="respiratory" post="tract disease: a randomized equivalence trial. Pediatr Pulmonol. 2008;43(2):142â€�149.18085694"/>
  <result pre="trial. Pediatr Pulmonol. 2008;43(2):142â€�149.18085694 27KewKM, UndelaK, KotortsiI, FerraraG. Macrolides for" exact="chronic" post="asthma. Cochrane Database Syst Rev. 2015;9:CD002997. 28BrusselleGG, VandersticheleC, JordensP,"/>
  <result pre="JordensP, et al. Azithromycin for prevention of exacerbations in severe" exact="asthma" post="(AZISAST): a multicentre randomised doubleâ€�blind placeboâ€�controlled trial. Thorax. 2013;68(4):322â€�329.23291349"/>
  <result pre="2013;68(4):322â€�329.23291349 29GibsonPG, YangIA, UphamJW, et al. Effect of azithromycin on" exact="asthma" post="exacerbations and quality of life in adults with persistent"/>
  <result pre="asthma exacerbations and quality of life in adults with persistent" exact="uncontrolled" post="asthma (AMAZES): a randomised, doubleâ€�blind, placeboâ€�controlled trial. Lancet. 2017;390(10095):659â€�668.28687413"/>
  <result pre="exacerbations and quality of life in adults with persistent uncontrolled" exact="asthma" post="(AMAZES): a randomised, doubleâ€�blind, placeboâ€�controlled trial. Lancet. 2017;390(10095):659â€�668.28687413 30JohnstonSL,"/>
  <result pre="BlasiF, BlackPN, MartinRJ, FarrellDJ, NiemanRB. The effect of telithromycin in" exact="acute" post="exacerbations of asthma. N Engl J Med. 2006;354(15):1589â€�1600.16611950 31JohnstonSL,"/>
  <result pre="31JohnstonSL, PattemorePK, SandersonG, et al. Community study of role of" exact="viral" post="infections in exacerbations of asthma in 9â€�11 year old"/>
  <result pre="PattemorePK, SandersonG, et al. Community study of role of viral" exact="infections" post="in exacerbations of asthma in 9â€�11 year old children."/>
  <result pre="Community study of role of viral infections in exacerbations of" exact="asthma" post="in 9â€�11 year old children. BMJ. 1995;310(6989):1225â€�1229.7767192 32KellyJT, BusseWW."/>
  <result pre="Haemophilus influenzae predicts response to azithromycin in adults with persistent" exact="uncontrolled" post="asthma. Eur Respir J. 2020;2000194. doi:10.1183/13993003.00194-2020. 35SajjanUS, JiaY, NewcombDC,"/>
  <result pre="doi:10.1183/13993003.00194-2020. 35SajjanUS, JiaY, NewcombDC, et al. H. influenzae potentiates airway" exact="epithelial" post="cell responses to rhinovirus by increasing ICAMâ€�1 and TLR3"/>
  <result pre="J. 2006;20(12):2121â€�2123.16914605 36JangYJ, KwonHJ, LeeBJ. Effect of clarithromycin on rhinovirusâ€�16" exact="infection" post="in A549 cells. Eur Respir J. 2006;27(1):12â€�19.16387930 37StroherU, DiCaroA,"/>
  <result pre="cells. Eur Respir J. 2006;27(1):12â€�19.16387930 37StroherU, DiCaroA, LiY, et al." exact="Severe" post="acute respiratory syndromeâ€�related coronavirus is inhibited by interferonâ€�alpha. J"/>
  <result pre="Eur Respir J. 2006;27(1):12â€�19.16387930 37StroherU, DiCaroA, LiY, et al. Severe" exact="acute" post="respiratory syndromeâ€�related coronavirus is inhibited by interferonâ€�alpha. J Infect"/>
  <result pre="Respir J. 2006;27(1):12â€�19.16387930 37StroherU, DiCaroA, LiY, et al. Severe acute" exact="respiratory" post="syndromeâ€�related coronavirus is inhibited by interferonâ€�alpha. J Infect Dis."/>
  <result pre="Dis. 2004;189(7):1164â€�1167.15031783 38LokugamageKG, HageA, SchindewolfC, RajsbaumR, MenacheryVD.SARSâ€�CoVâ€�2 is sensitive to" exact="type I" post="interferon pretreatment. bioRxiv. 2020. 39SuzukiT, YamayaM, SekizawaK, et al."/>
  <result pre="bioRxiv. 2020. 39SuzukiT, YamayaM, SekizawaK, et al. Erythromycin inhibits rhinovirus" exact="infection" post="in cultured human tracheal epithelial cells. Am J Respir"/>
  <result pre="et al. Erythromycin inhibits rhinovirus infection in cultured human tracheal" exact="epithelial" post="cells. Am J Respir Crit Care Med. 2002;165(8):1113â€�1118.11956054 40SuzukiT,"/>
  <result pre="2002;165(8):1113â€�1118.11956054 40SuzukiT, YamayaM, SekizawaK, et al. Bafilomycin A(1) inhibits rhinovirus" exact="infection" post="in human airway epithelium: effects on endosome and ICAMâ€�1."/>
  <result pre="ShinyaK, HatachiY, et al. Clarithromycin inhibits type a seasonal influenza" exact="virus infection" post="in human airway epithelial cells. J Pharmacol Exp Ther."/>
  <result pre="HatachiY, et al. Clarithromycin inhibits type a seasonal influenza virus" exact="infection" post="in human airway epithelial cells. J Pharmacol Exp Ther."/>
  <result pre="inhibits type a seasonal influenza virus infection in human airway" exact="epithelial" post="cells. J Pharmacol Exp Ther. 2010;333(1):81â€�90.20040578 43TranDH, SugamataR, HiroseT,"/>
  <result pre="et al. Azithromycin, a 15â€�membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09" exact="virus infection" post="by interfering with virus internalization process. J Antibiot (Tokyo)."/>
  <result pre="al. Azithromycin, a 15â€�membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus" exact="infection" post="by interfering with virus internalization process. J Antibiot (Tokyo)."/>
  <result pre="al. Leucomycin A3, a 16â€�membered macrolide antibiotic, inhibits influenza A" exact="virus infection" post="and disease progression. J Antibiot (Tokyo). 2014;67(3):213â€�222.24496145 46FageC, PizzornoA,"/>
  <result pre="Leucomycin A3, a 16â€�membered macrolide antibiotic, inhibits influenza A virus" exact="infection" post="and disease progression. J Antibiot (Tokyo). 2014;67(3):213â€�222.24496145 46FageC, PizzornoA,"/>
  <result pre="a 16â€�membered macrolide antibiotic, inhibits influenza A virus infection and" exact="disease" post="progression. J Antibiot (Tokyo). 2014;67(3):213â€�222.24496145 46FageC, PizzornoA, RheaumeC, AbedY,"/>
  <result pre="WalterMJ. Azithromycin attenuates airway inflammation in a mouse model of" exact="viral" post="bronchiolitis. Respir Res. 2010;11:90.20591166 48de WitE, van DoremalenN, FalzaranoD,"/>
  <result pre="SchaffnerC, BrownK, et al. Azithromycin blocks autophagy and may predispose" exact="cystic fibrosis" post="patients to mycobacterial infection. J Clin Invest. 2011;121(9):3554â€�3563.21804191 53AndreaniJ,"/>
  <result pre="without concomitant azithromycin among hospitalized patients testing positive for coronavirus" exact="disease" post="2019 (COVIDâ€�19). JAMA Cardiol. 2020;e201834. doi:10.1001/jamacardio.2020.1834. 56MaisonnasseP, GuedjJ, ContrerasV,"/>
  <result pre="doi:10.1001/jamacardio.2020.1834. 56MaisonnasseP, GuedjJ, ContrerasV, et al. Hydroxychloroquine use against SARSâ€�CoVâ€�2" exact="infection" post="in nonâ€�human primates. Nature. 2020doi:10.1038/s41586-020-2558-4. 57BuonaguroFM, AsciertoPA, MorseGD, et"/>
  <result pre="et al. A randomised controlled trial of azithromycin to prevent" exact="chronic" post="rejection after lung transplantation. Eur Respir J. 2011;37(1):164â€�172.20562124 60AltenburgJ,"/>
  <result pre="61HuiD, YanF, ChenRH. The effects of azithromycin on patients with" exact="diffuse" post="panbronchiolitis: a retrospective study of 29 cases. J Thorac"/>
  <result pre="AzumaA, YamamotoM, IzumiT, AndoM. Improvement of survival in patients with" exact="diffuse" post="panbronchiolitis treated with lowâ€�dose erythromycin. Am J Respir Crit"/>
  <result pre="TamuraA, KurashimaA. Longâ€�term lowâ€�dose administration of erythromycin to patients with" exact="diffuse" post="panbronchiolitis. Respiration. 1991;58(3â€&quot;4):145â€�149.1745845 64WengD, WuQ, ChenXQ, et al. Azithromycin"/>
  <result pre="panbronchiolitis. Respiration. 1991;58(3â€&quot;4):145â€�149.1745845 64WengD, WuQ, ChenXQ, et al. Azithromycin treats" exact="diffuse" post="panbronchiolitis by targeting T cells via inhibition of mTOR"/>
  <result pre="activates nuclear factor kappaB and activator protein 1 in human" exact="vascular" post="smooth muscle and induces cellular proliferation. J Surg Res."/>
  <result pre="factor kappaB and activator protein 1 in human vascular smooth" exact="muscle" post="and induces cellular proliferation. J Surg Res. 2000;90(1):76â€�81.10781378 67SrivastavaP,"/>
  <result pre="kinase mediated pathway and inhibits inflammatory cytokines and chemokines in" exact="epithelial" post="cells from infertile women with recurrent Chlamydia trachomatis infection."/>
  <result pre="cytokines and chemokines in epithelial cells from infertile women with" exact="recurrent" post="Chlamydia trachomatis infection. DNA Cell Biol. 2011;30(8):545â€�554.21438755 68RolfeFG, ValentineJE,"/>
  <result pre="inhibit IL17â€�induced IL8 and 8â€�isoprostane release from human airway smooth" exact="muscle" post="cells. Am J Transplant. 2007;7(1):76â€�82.17061983 71NieYC, WuH, LiPB, et"/>
  <result pre="Erythromycin and clarithromycin attenuate cytokineâ€�induced endothelinâ€�1 expression in human bronchial" exact="epithelial" post="cells. Eur Respir J. 1998;12(1):57â€�63.9701415 73TytecaD, SchanckA, DufreneYF, et"/>
  <result pre="polymorphonuclear neutrophils and sputum during longâ€�term therapy in patients with" exact="cystic fibrosis." post="Ther Drug Monit. 2006;28(2):219â€�225.16628134 78WildfeuerA, LaufenH, ZimmermannT. Distribution of"/>
  <result pre="et al. Azithromycin reduces spontaneous and induced inflammation in DeltaF508" exact="cystic fibrosis" post="mice. Respir Res. 2006;7:134.17064416 91BosnarM, BosnjakB, CuzicS, et al."/>
  <result pre="BosnjakB, CuzicS, et al. Azithromycin and clarithromycin inhibit lipopolysaccharideâ€�induced murine" exact="pulmonary" post="neutrophilia mainly through effects on macrophageâ€�derived granulocyteâ€�macrophage colonyâ€�stimulating factor"/>
  <result pre="function. Int Immunopharmacol. 2012;13(1):8â€�14.22410149 99YamasawaH, OshikawaK, OhnoS, SugiyamaY. Macrolides inhibit" exact="epithelial" post="cellâ€�mediated neutrophil survival by modulating granulocyte macrophage colonyâ€�stimulating factor"/>
  <result pre="Azithromycin has an antiproliferative and autophagic effect on airway smooth" exact="muscle" post="cells. Eur Respir J. 2009;34(3):721â€�730.19386688 101DaenasC, HatziefthimiouAA, GourgoulianisKI, MolyvdasPA."/>
  <result pre="ERK phosphorylation and ILâ€�8 and GMâ€�CSF production by human bronchial" exact="epithelial" post="cells. Am J Physiol Lung Cell Mol Physiol. 2006;290(1):L75â€�L85.16085674"/>
  <result pre="doubleâ€�blind, randomized, placeboâ€�controlled trial of macrolide in the treatment of" exact="chronic" post="rhinosinusitis. Laryngoscope. 2006;116(2):189â€�193.16467702 108YamadaT, FujiedaS, MoriS, YamamotoH, SaitoH. Macrolide"/>
  <result pre="Pharmacother. 1998;32(7â€&quot;8):785â€�793.9681095 110SerisierDJ. Risks of population antimicrobial resistance associated with" exact="chronic" post="macrolide use for inflammatory airway diseases. Lancet Respir Med."/>
  <result pre="Clin Pharmacol Ther. 2020;108(2):201â€�211.32302411 114CiganaC, AssaelBM, MelottiP. Azithromycin selectively reduces" exact="tumor" post="necrosis factor alpha levels in cystic fibrosis airway epithelial"/>
  <result pre="MelottiP. Azithromycin selectively reduces tumor necrosis factor alpha levels in" exact="cystic fibrosis" post="airway epithelial cells. Antimicrob Agents Chemother. 2007;51(3):975â€�981.17210769 115HuaW, LiuH,"/>
  <result pre="reduces tumor necrosis factor alpha levels in cystic fibrosis airway" exact="epithelial" post="cells. Antimicrob Agents Chemother. 2007;51(3):975â€�981.17210769 115HuaW, LiuH, XiaLX, et"/>
  <result pre="and telithromycin inhibit MUC5AC induction by Chlamydophila pneumoniae in airway" exact="epithelial" post="cells. Pulm Pharmacol Ther. 2009;22(6):580â€�586.19716898 118CiganaC, NicolisE, PasettoM, AssaelBM,"/>
  <result pre="118CiganaC, NicolisE, PasettoM, AssaelBM, MelottiP. Antiâ€�inflammatory effects of azithromycin in" exact="cystic fibrosis" post="airway epithelial cells. Biochem Biophys Res Commun. 2006;350(4):977â€�982.17045242 119YamauchiK,"/>
  <result pre="AssaelBM, MelottiP. Antiâ€�inflammatory effects of azithromycin in cystic fibrosis airway" exact="epithelial" post="cells. Biochem Biophys Res Commun. 2006;350(4):977â€�982.17045242 119YamauchiK, ShibataY, KimuraT,"/>
  <result pre="improves macrophage phagocytic function and expression of mannose receptor in" exact="chronic" post="obstructive pulmonary disease. Am J Respir Crit Care Med."/>
  <result pre="phagocytic function and expression of mannose receptor in chronic obstructive" exact="pulmonary" post="disease. Am J Respir Crit Care Med. 2008;178(2):139â€�148.18420960 121HodgeS,"/>
  <result pre="BrozynaS, JersmannH, HolmesM, ReynoldsPN. Azithromycin increases phagocytosis of apoptotic bronchial" exact="epithelial" post="cells by alveolar macrophages. Eur Respir J. 2006;28(3):486â€�495.16737992 122ArakiN,"/>
  <result pre="and secretion via inhibition of activator proteinâ€�1 in human airway" exact="epithelial" post="cells. Eur J Pharmacol. 2010;644(1â€&quot;3):209â€�214.20619258 123ShimizuT, ShimizuS, HattoriR, GabazzaEC,"/>
  <result pre="vitro effects of macrolide antibiotics on mucus secretion in airway" exact="epithelial" post="cells. Am J Respir Crit Care Med. 2003;168(5):581â€�587.12829454 124ShaoMX,"/>
  <result pre="NadelJA. Neutrophil elastase induces MUC5AC mucin production in human airway" exact="epithelial" post="cells via a cascade involving protein kinase C, reactive"/>
  <result pre="neutrophil elastase induces hypersecretion of mucin from wellâ€�differentiated human bronchial" exact="epithelial" post="cells in vitro via a protein kinase C{delta}â€�mediated mechanism."/>
  <result pre="2005;167(3):651â€�661.16127146 126HalldorssonS, GudjonssonT, GottfredssonM, SinghPK, GudmundssonGH, BaldurssonO. Azithromycin maintains airway" exact="epithelial" post="integrity during Pseudomonas aeruginosa infection. Am J Respir Cell"/>
  <result pre="ShiL, WangY, et al. Pathological findings of COVIDâ€�19 associated with" exact="acute" post="respiratory distress syndrome. Lancet Respir Med. 2020;8:420â€�422.32085846 129RuanQ, YangK,"/>
  <result pre="WangY, et al. Pathological findings of COVIDâ€�19 associated with acute" exact="respiratory" post="distress syndrome. Lancet Respir Med. 2020;8:420â€�422.32085846 129RuanQ, YangK, WangW,"/>
  <result pre="pathogenic GMâ€�CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe" exact="pulmonary" post="syndrome patients of a new coronavirus. bioRxiv2020. 132collab: RECOVERY"/>
  <result pre="GMâ€�CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary" exact="syndrome" post="patients of a new coronavirus. bioRxiv2020. 132collab: RECOVERY Collaborative"/>
 </snippets>
</snippetsTree>
